OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
, , , und | 17. Dez. 2015
Über diesen Artikel
Online veröffentlicht: 17. Dez. 2015
Seitenbereich: 1 - 7
Eingereicht: 18. Sept. 2015
Akzeptiert: 30. Sept. 2015
DOI: https://doi.org/10.1515/fco-2015-0014
Schlüsselwörter
© 2015
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer